Aclaris Therapeutics Inc
NASDAQ:ACRS

Watchlist Manager
Aclaris Therapeutics Inc Logo
Aclaris Therapeutics Inc
NASDAQ:ACRS
Watchlist
Price: 4.53 USD 2.49% Market Closed
Market Cap: $490.8m

Operating Margin

-973.9%
Current
Declining
by 529%
vs 3-y average of -444.9%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-973.9%
=
Operating Income
$-153.3m
/
Revenue
$15.7m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-973.9%
=
Operating Income
$-153.3m
/
Revenue
$15.7m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Aclaris Therapeutics Inc
NASDAQ:ACRS
490.8m USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
Loading...
US
Johnson & Johnson
NYSE:JNJ
525.7B USD
Loading...
CH
Roche Holding AG
SIX:ROG
276.7B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
211.5B GBP
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK
Loading...
CH
Novartis AG
SIX:NOVN
221.8B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
271.6B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
146B USD
Loading...

Market Distribution

Lower than 93% of companies in the United States of America
Percentile
7th
Based on 14 112 companies
7th percentile
-973.9%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Aclaris Therapeutics Inc
Glance View

Market Cap
490.8m USD
Industry
Pharmaceuticals

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. The company is headquartered in Wayne, Pennsylvania and currently employs 75 full-time employees. The company went IPO on 2015-10-07. The firm is focused on leveraging its experience in drug discovery and development and kinase inhibition to develop small molecule therapies to help people impacted immuno-inflammatory conditions. The Company’s drug candidates are Zunsemetinib (ATI-450), ATI-1777 and ATI-2138. The Company’s ATI-450, an investigational oral, small molecule selective MK2 inhibitor compound, for the treatment of rheumatoid arthritis. Its ATI-1777, an investigational topical soft-JAK 1/3 inhibitor compound, for the treatment of atopic dermatitis. The firm is engaged in developing ATI-2138, its investigational oral inhibitor compound, as a potential treatment for T-cell mediated autoimmune diseases. The company is also developing oral gut biased JAK inhibitors, as a potential treatment for inflammatory bowel disease.

ACRS Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-973.9%
=
Operating Income
$-153.3m
/
Revenue
$15.7m
What is Aclaris Therapeutics Inc's current Operating Margin?

The current Operating Margin for Aclaris Therapeutics Inc is -973.9%, which is below its 3-year median of -444.9%.

How has Operating Margin changed over time?

Over the last 3 years, Aclaris Therapeutics Inc’s Operating Margin has decreased from -356.9% to -973.9%. During this period, it reached a low of -973.9% on Sep 30, 2025 and a high of -171% on Sep 30, 2024.

Back to Top